

SIGA

Company Overview

A Leader in Health Security
& Infectious Diseases

March 2024



Forward Looking Statements

The statements made in this presentation may include forward-looking statements regarding the treatment of smallpox and other orthopoxvirus infections, the development and attributes of SIGA Technologies, Inc. (“SIGA”) products, and the future operations, opportunities or financial performance of SIGA. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimations based upon the information available to SIGA as of the date of this presentation. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements.


Undue reliance should not be placed on forward looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.

For a more detailed discussion of our risks, see the Risk Factors section in SIGA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC and our other filings with the SEC, including our most recent Quarterly Report, all of which are available on our website, www.siga.com.

Contents

- 1** Introduction
- 2** The Era of Emerging Viruses
- 3** TPOXX[®] Differentiated Products Focused on Infectious Diseases
- 4** Growth Strategy
- 5** Financial Summary


SIGA at a Glance



Stellar Revenue Generation
 >\$1bn of Procurement Contracts
 from 10+ years Working with
 Governments




TPOXX
 A Foundational Franchise &
 Trusted Treatment for
 Smallpox & Mpox



Strong Expertise
 Infectious Disease, Public
 Health, and Government
 Contracting



25+ Countries
 Where Products
 Are Sold



**Revenues
 by Geography⁽¹⁾**

SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focused on providing **solutions** for **unmet needs** in emerging **infectious diseases**. The company is headquartered in New York City, with research and development facilities in Corvallis, Oregon.

(1) From 2020 – 2023

SIGA is a Leader in Health Security and Infectious Disease

Fully Integrated Infectious Disease Capabilities

Highly profitable, commercial stage pharmaceutical company operating within infectious disease and health security

Experienced senior management team with **deep expertise in commercial, antiviral R&D, and government contracting & relations**

Fully integrated, **US-based operational supply chain**

Leading TPOXX Product Platform

Lead product is oral TPOXX, an antiviral drug treating smallpox (FDA approved in 2018) and orthopox (EMA approved in 2022)

Only one of two approved antivirals for orthopox treatment; distinct mechanism of action supports superior efficacy and safety profile

Track record of securing multi-year government awards across multiple agencies

Foundation for Continued Attractive Growth

Near term opportunities for TPOXX indication expansions (mpox in US, Post-Exposure Prophylaxis "PEP", pediatric formulation)

Geographical expansion ex-US, including Canada, Europe, ROW

Able to leverage antiviral and strong government procurement capabilities to move into complementary therapeutic areas with similar points of patient care

Attractive inorganic growth opportunities to expand into adjacencies and therapeutic areas with scientific and commercial synergies

Best-in-Class Financial Performance

Realized **~\$500 mm of TPOXX revenue with robust gross margins** in 2020 – 2023

Highly profitable company with **~\$300 mm in pre-tax operating income** in 2020 – 2023

Robust balance sheet and cash flow with **minimal CAPEX and no debt**

Executing on our Strategy for Growth



KEY TRENDS

Greater **awareness** on the need for **preparedness** in the event of an outbreak

Increasing societal **vulnerability** to orthopox viruses

Increased **risk of natural, accidental or intentional** outbreaks

COMPETITIVE ADVANTAGE

Government Contracting & Relations

Supply & Distribution

Regulatory & Development

Best-in-Class Product

Operating Model

Public Health

STRATEGIC PRIORITIES

Advance regulatory approvals for TPOXX in new formulations & indications

Cultivate strategic partnerships to expand global access to TPOXX

Leverage capabilities to move into complementary therapeutics areas


Resulting in:

- Strong Financial Performance**
- Robust Balance Sheet & Cash Flow**
- Shareholder Value Creation**

Comprehensive Capabilities Provide Strong Foundation



Entrenched relationships with key government agencies
Positive track-record of contract performance



Proven R&D capabilities
Close coordination with government agencies to jointly develop high-impact therapies
Ongoing label expansions for TPOXX

Fully integrated US end-to-end supply chain network



Experienced Leadership in Infectious Diseases and Government Relations



Diem Nguyen, PhD, MBA
Chief Executive Officer

Visionary: Spearheaded \$11 bn revenue global operating units that generated one third of Pfizer's annual profit



Dan Luckshire
Chief Financial Officer

Operational Excellence and Financial Integrity Leader: Demonstrated leadership in finance, investment banking, and commercial operations



Jay Varma, MD
Chief Medical Officer

Public Health Guru: Led public health programs and outbreak responses in Asia, Africa, and US that saved hundreds of millions of lives




Dennis Hruby
Chief Scientific Officer

World Renowned Infectious Disease Researcher: Led the discovery, development, and approval of TPOXX



Tove Bolken
SVP, Operations and Chief Supply Chain Officer

Flawless Operator: Managed manufacturing, process development and supply chain oversight



Recently Appointed
General Counsel

Strategic Partner: Experienced lawyer with breadth of capabilities in corporate law, M&A, and public companies

Persistent, Durable Financial Performance Over Time

Revenues (\$mm)




Pre-tax Operating Income (\$mm)



Capital Management⁽¹⁾ (\$mm)



Averages for 2020 – 2023 (\$mm)




(1) Includes dividends and share repurchases


The Era of Emerging Viruses

SIGA

The Emergence of New Viruses Threaten Health Security



Orthopox Threatens Global Health through Natural Occurrence or Potential Bioweapon Warfare



Mpox surge in Congo raises concerns world will ignore warnings again



Research with exotic viruses risks a deadly outbreak, scientists warn



Smallpox is still a threat to America, 40 years after its eradication




11:37
Safari
Covid-19 Guidance > Symptoms and Treatment JN.1 Variant Ne
NEWS ANALYSIS
New Infectious Threats Are Coming. The U.S. Probably Won't Contain Them.
The coronavirus revealed flaws in the nation's pandemic plans. The spread of monkeypox shows that the problems remain deeply entrenched.

11:35
Post
Siga Technologies @SigaTech Follow
"Somebody would reconstruct, say, a smallpox virus and have that spread, and that would not only kill millions, it could potentially kill billions"
– Bill Gates on bioterrorism, 2017, PBS

Smallpox Remains a Significant Threat Today

Highly contagious and fatal disease in susceptible population



2022 Mpox Global Outbreak Demonstrates the Need for Orthopox Antiviral Therapies

2022 mpox Outbreak

Mpox belongs to orthopox family
Lesions are extremely painful with weeks to months of recovery
In 2022, global mpox outbreak impacted >90,000 cases
Case fatality >160 deaths

Rapid Containment Response

TPOXX quickly identified as a potentially effective treatment
In the US, the CDC distributed 80,000+ bottles of oral TPOXX and 13,000+ vials of IV TPOXX under EAU

Ongoing Threat

CDC and WHO agencies concerned mpox⁽¹⁾ is a forewarning of graver threats
Ongoing outbreak in the DRC with 12,000+ cases and 581 deaths since January 2023
Caused by Clade 1 with case-fatality far greater than the 2022 strain (~5-10%)
CDC issued a health alert in December 2023

FDA, NIH and CDC have been Working to Support the Expanded Access Use of TPOXX

(1) TPOXX is approved for mpox in Europe

TPOXX Differentiated
Products Focused on
Infectious Disease



SIGA

Orthopox Family Encompasses a Spectrum of Diverse Diseases

Orthopoxvirus infections can cause a range of febrile rash illnesses in humans, from fairly benign, localized skin infections to severe systemic infections. There are four orthopoxvirus species known to cause human disease:

VARIOLA VIRUS (SMALLPOX)

Causative agent of smallpox; TPOXX received FDA approval for treatment in 2018.

COWPOX VIRUS

Human cowpox virus infection is classically associated with occupational exposure to cattle; however, other animals, including rats, pet cats, and zoo and circus elephants, have been implicated. Infection can be lethal in immunocompromised individuals.


MPOX VIRUS

Mpox virus causes intermittent human infections, primarily in Central and West Africa, although isolated outbreaks have been identified in the United States and Sudan; the disease is very similar to smallpox. Case fatality rates range from <1% to >10% depending on virus clade.

VACCINIA VIRUS

Vaccinia virus is used as the smallpox vaccine and some cancer therapies in development. It causes sporadic disease in those immunized/treated, contacts of those immunized/treated, and laboratory workers. Infection can be lethal in immunocompromised individuals.

TPOXX is Clinically Differentiated Medical Countermeasure for Orthopox



TPOXX Demonstrates Strong Safety and Efficacy in Humans

TPOXX a Critical Antiviral Countermeasure Stockpiled by the US Government

The COVID-19 pandemic and mpox outbreak have increased government focus on health security preparedness

**SMALLPOX ANTIVIRAL
IN THE US STOCKPILE (SNS)**

TREATMENT	1.7 mm courses
POST-EXPOSURE PROPHYLAXIS (PEP)	1.7 mm PEP courses = 3.4 mm treatment courses

- ✓ **Effective use of antiviral drugs** would reduce fatalities
- ✓ **Antivirals for PEP** is a **key strategy to minimize fatalities**

In addition to SNS, the DOD has Procured TPOXX since 2022 and is in the Process of Establishing a Formal Requirement for TPOXX

Demonstrated Track-Record of >\$1B Successful Long-Standing Government Contracts for TPOXX


	2011 TPOXX CONTRACT	2018 TPOXX CONTRACT
PROCUREMENT DURATION	2011-2018	2018-current
KEY AGENCY INVOLVED	US Biomedical Advanced Research and Dev. Authority ("BARDA") 	US Biomedical Advanced Research and Dev. Authority ("BARDA") 
CONTRACT VALUE	<ul style="list-style-type: none"> ▪ \$461 mm total procurement contract value ▪ \$461 mm fully delivered 	<ul style="list-style-type: none"> ▪ \$546 mm total procurement contract value ▪ \$408 mm ordered; \$341 mm delivered as of 12/31/2023; \$138 mm outstanding options

New Contract with Administration for Strategic Preparedness & Response (ASPR) for US National Stockpile Targeted in 2024

Growth Strategy



Overview of Growth Opportunities



Advancing TPOXX Regulatory Approvals to Accelerate Growth into New Formulations and Indications

TPOXX Franchise is the Foundation for Expansion
with over \$1bn in Multi-Year Contracts

PEP Program (post-exposure prophylaxis)

Addresses **time gap** between exposure and signs of clinical infection

Studies are supportive of the use of TPOXX in PEP to **reduce morbidity and mortality**

Targeting FDA **submission** within 12 months

Mpox Program

Critical to provide in countries where not approved for this virus

Conducting 5 randomized controlled **trials** (RCT) and multiple observational studies

Working with government sponsors and FDA on **pathway to submission**

Pediatric Program

Important program to protect the pediatric **population**


Completed trial that demonstrates **equivalence of drug exposure** in volunteers (oral vs liquid formulation)

Designing **clinical program** to support regulatory filing

Selected a **manufacturer** to prepare clinical supplies

TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox


PEP program has received \$27 mm of development funding from US Department of Defense



“The reality is that [smallpox] is so **highly infectious**, that **post-exposure prophylaxis** is going to be a knee-jerk reaction to anybody at any time if you've got anybody who's been diagnosed. So anybody who's within eyeball shot of somebody who's got a diagnosed case of smallpox is going to be getting [TPOXX].”

-- Colonel Peter Weina, MD, the Chief of Research at Walter Reed Military Medical Center US FDA Antimicrobial Drugs Advisory Committee, May 1, 2018

Pursuing TPOXX US Label Expansion for Mpox



Cultivate Partnerships to Expand Global Access

Collaborating with Governments and Other Partners on Health Security is Best-in-Class Core Competency

Strong Long-Standing Partnerships

- Public Health Emergency Medical Countermeasures Enterprise (PHEMCE)
- Biomedical Advanced Research and Development Authority (BARDA)
- Stockpiling Lifesaving Medical Countermeasures
- US Department of Defense



Proven Track Record

- Secured funding for over \$1 bn in multi-year contracts for TPOXX
- Sold +\$100 mm of TPOXX to more than 25 countries since 2020

Common Goal of Global Health Security

- Shared understanding that with the current geopolitical environment, the risk of a rogue actor or nation weaponizing a virus has increased
- Clear recognition of the need to stockpile TPOXX and other critical medicines in the event of an outbreak to quickly contain the impact

SIGA is the Preferred Partner for Key Government Stakeholders



Public Health Emergency Medical Countermeasures Enterprise (PHEMCE)

- PHEMCE led by HHS Office of the Assistant Secretary for Preparedness and Response (ASPR)
- Primary internal agency partners: CDC, FDA, NIH
- Interagency partners include the Department of Defense (DoD)



Biomedical Advanced Research and Development Authority (BARDA)

- BARDA supports the transition of medical countermeasures from research to FDA approval
- Provides funding, technical assistance, and core services
- Aim to include approved products in the Strategic National Stockpile



Stockpiling Lifesaving Medical Countermeasures

- Division of CBRN MCMs develops and establishes stockpiles of vaccines, drugs, and diagnostics against CBRN threats
- Project BioShield Act of 2004 created the Special Reserve Fund (SRF) with a \$5.6B appropriation (2004 - 2013)
- SRF aimed to accelerate research, development, and acquisition of MCMs against CBRN threat agents



Department of Defense

- Defense Threat Reduction Agency (DTRA) focuses on protecting American warfighters and allies from chemical and biological threats
- Provides support to military services, combatant commands, and international partners
- Engages in innovating technologies for detecting chemical and biological threats

Financial Summary

SIGA

Strong Financial Performance

1 US Government Orders under Current Contracts

- ~\$400 mm of TPOXX (1.2 mm courses) ordered for SNS over the past 4 years
- ~\$11 mm of oral TPOXX ordered by the Department of Defense in 2023

2 International Orders

- Over \$100 mm of international oral TPOXX ordered by more than 25 countries since 2020


3 Financial Results

- Cumulative pre-tax operating income of ~\$300 mm for the 2020 – 2023 time period
- 2023 product sales of \$131 mm and pre-tax operating income of \$84 mm

(\$ in millions)

	FY 2020	FY 2021	FY 2022	FY 2023
Product Sales				
Oral TPOXX (US Government)	\$113	\$113	\$7	\$110
Oral TPOXX (International)	\$2	\$13	\$71	\$21
IV TPOXX	---	---	\$7	---
Total Product Sales	\$115	\$127	\$87	\$131
Pre-Tax Operating Income	\$85	\$89	\$43	\$84
Net Income	\$56	\$69	\$34	\$68

Key Takeaways



We are Well Positioned for Growth and Attractive Returns Over Time